The JI
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     
 


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Visintin, A.
Right arrow Articles by Golenbock, D. T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Visintin, A.
Right arrow Articles by Golenbock, D. T.
Right arrowPubmed/NCBI databases
*Compound via MeSH
*Substance via MeSH
The Journal of Immunology, 2005, 175: 6465-6472.
Copyright © 2005 by The American Association of Immunologists

Pharmacological Inhibition of Endotoxin Responses Is Achieved by Targeting the TLR4 Coreceptor, MD-21

Alberto Visintin2, Kristen A. Halmen, Eicke Latz, Brian G. Monks and Douglas T. Golenbock

Division of Infectious Diseases and Immunology, University of Massachusetts Medical School, Worcester, MA 01655

The detection of Gram-negative LPS depends upon the proper function of the TLR4-MD-2 receptor complex in immune cells. TLR4 is the signal transduction component of the LPS receptor, whereas MD-2 is the endotoxin-binding unit. MD-2 appears to activate TLR4 when bound to TLR4 and ligated by LPS. Only the monomeric form of MD-2 was found to bind LPS and only monomeric MD-2 interacts with TLR4. Monomeric MD-2 binds TLR4 with an apparent Kd of 12 nM; this binding avidity was unaltered in the presence of endotoxin. E5564, an LPS antagonist, appears to inhibit cellular activation by competitively preventing the binding of LPS to MD-2. Depletion of endogenous soluble MD-2 from human serum, with an immobilized TLR4 fusion protein, abrogated TLR4-mediated LPS responses. By determining the concentration of added-back MD-2 that restored normal LPS responsiveness, the concentration of MD-2 was estimated to be ~50 nM. Similarly, purified TLR4-Fc fusion protein, when added to the supernatants of TLR4-expressing cells in culture, inhibited the interaction of MD-2 with TLR4, thus preventing LPS stimulation. The ability to inhibit the effects of LPS as a result of the binding of TLR4-Fc or E5564 to MD-2 highlights MD-2 as the logical target for drug therapies designed to pharmacologically intervene against endotoxin-induced disease.




This article has been cited by other articles:


Home page
J. Immunol.Home page
J. Vasl, A. Oblak, T. L. Gioannini, J. P. Weiss, and R. Jerala
Novel Roles of Lysines 122, 125, and 58 in Functional Differences between Human and Murine MD-2
J. Immunol., October 15, 2009; 183(8): 5138 - 5145.
[Abstract] [Full Text] [PDF]


Home page
BrainHome page
K. M. Rodgers, M. R. Hutchinson, A. Northcutt, S. F. Maier, L. R. Watkins, and D. S. Barth
The cortical innate immune response increases local neuronal excitability leading to seizures
Brain, September 1, 2009; 132(9): 2478 - 2486.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
M. Mancek-Keber, H. Gradisar, M. I. Pestana, G. M. de Tejada, and R. Jerala
Free Thiol Group of MD-2 as the Target for Inhibition of the Lipopolysaccharide-induced Cell Activation
J. Biol. Chem., July 17, 2009; 284(29): 19493 - 19500.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Gastrointest. Liver Physiol.Home page
R. Ungaro, M. Fukata, D. Hsu, Y. Hernandez, K. Breglio, A. Chen, R. Xu, J. Sotolongo, C. Espana, J. Zaias, et al.
A novel Toll-like receptor 4 antagonist antibody ameliorates inflammation but impairs mucosal healing in murine colitis
Am J Physiol Gastrointest Liver Physiol, June 1, 2009; 296(6): G1167 - G1179.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
O. Sandanger, L. Ryan, J. Bohnhorst, A.-C. Iversen, H. Husebye, O. Halaas, L. Landro, P. Aukrust, S. S. Froland, G. Elson, et al.
IL-10 Enhances MD-2 and CD14 Expression in Monocytes and the Proteins Are Increased and Correlated in HIV-Infected Patients
J. Immunol., January 1, 2009; 182(1): 588 - 595.
[Abstract] [Full Text] [PDF]


Home page
Innate ImmunityHome page
D. P. Rossignol, N. Wong, R. Noveck, and M. Lynn
Continuous pharmacodynamic activity of eritoran tetrasodium, a TLR4 antagonist, during intermittent intravenous infusion into normal volunteers
Innate Immunity, December 1, 2008; 14(6): 383 - 394.
[Abstract] [PDF]


Home page
J. Biol. Chem.Home page
A. Teghanemt, R. L. Widstrom, T. L. Gioannini, and J. P. Weiss
Isolation of Monomeric and Dimeric Secreted MD-2: ENDOTOXIN{middle dot}sCD14 AND TOLL-LIKE RECEPTOR 4 ECTODOMAIN SELECTIVELY REACT WITH THE MONOMERIC FORM OF SECRETED MD-2
J. Biol. Chem., August 8, 2008; 283(32): 21881 - 21889.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
K. L. Lloyd-Jones, M. M. Kelly, and P. Kubes
Varying Importance of Soluble and Membrane CD14 in Endothelial Detection of Lipopolysaccharide
J. Immunol., July 15, 2008; 181(2): 1446 - 1453.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
V. Jain, A. Halle, K. A. Halmen, E. Lien, M. Charrel-Dennis, S. Ram, D. T. Golenbock, and A. Visintin
Phagocytosis and intracellular killing of MD-2 opsonized Gram-negative bacteria depend on TLR4 signaling
Blood, May 1, 2008; 111(9): 4637 - 4645.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
J. Ngampasutadol, S. Ram, S. Gulati, S. Agarwal, C. Li, A. Visintin, B. Monks, G. Madico, and P. A. Rice
Human Factor H Interacts Selectively with Neisseria gonorrhoeae and Results in Species-Specific Complement Evasion
J. Immunol., March 1, 2008; 180(5): 3426 - 3435.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
M. Davey, X. Liu, T. Ukai, V. Jain, C. Gudino, F. C. Gibson III, D. Golenbock, A. Visintin, and C. A. Genco
Bacterial Fimbriae Stimulate Proinflammatory Activation in the Endothelium through Distinct TLRs
J. Immunol., February 15, 2008; 180(4): 2187 - 2195.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
A. Teghanemt, F. Re, P. Prohinar, R. Widstrom, T. L. Gioannini, and J. P. Weiss
Novel Roles in Human MD-2 of Phenylalanines 121 and 126 and Tyrosine 131 in Activation of Toll-like Receptor 4 by Endotoxin
J. Biol. Chem., January 18, 2008; 283(3): 1257 - 1266.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
P. Rallabhandi, A. Awomoyi, K. E. Thomas, A. Phalipon, Y. Fujimoto, K. Fukase, S. Kusumoto, N. Qureshi, M. B. Sztein, and S. N. Vogel
Differential Activation of Human TLR4 by Escherichia coli and Shigella flexneri 2a Lipopolysaccharide: Combined Effects of Lipid A Acylation State and TLR4 Polymorphisms on Signaling
J. Immunol., January 15, 2008; 180(2): 1139 - 1147.
[Abstract] [Full Text] [PDF]


Home page
J. Leukoc. Biol.Home page
H. Gradisar, M. M. Keber, P. Pristovsek, and R. Jerala
MD-2 as the target of curcumin in the inhibition of response to LPS
J. Leukoc. Biol., October 1, 2007; 82(4): 968 - 974.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
R. T. Figueiredo, P. L. Fernandez, D. S. Mourao-Sa, B. N. Porto, F. F. Dutra, L. S. Alves, M. F. Oliveira, P. L. Oliveira, A. V. Graca-Souza, and M. T. Bozza
Characterization of Heme as Activator of Toll-like Receptor 4
J. Biol. Chem., July 13, 2007; 282(28): 20221 - 20229.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
P. Prohinar, F. Re, R. Widstrom, D. Zhang, A. Teghanemt, J. P. Weiss, and T. L. Gioannini
Specific High Affinity Interactions of Monomeric Endotoxin{middle dot}Protein Complexes with Toll-like Receptor 4 Ectodomain
J. Biol. Chem., January 12, 2007; 282(2): 1010 - 1017.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
C. Nishitani, H. Mitsuzawa, H. Sano, T. Shimizu, N. Matsushima, and Y. Kuroki
Toll-like Receptor 4 Region Glu24-Lys47 Is a Site for MD-2 Binding: IMPORTANCE OF CYS29 AND CYS40
J. Biol. Chem., December 15, 2006; 281(50): 38322 - 38329.
[Abstract] [Full Text] [PDF]


Home page
J. Leukoc. Biol.Home page
A. Visintin, K. A. Halmen, N. Khan, B. G. Monks, D. T. Golenbock, and E. Lien
MD-2 expression is not required for cell surface targeting of Toll-like receptor 4 (TLR4)
J. Leukoc. Biol., December 1, 2006; 80(6): 1584 - 1592.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
H. Mitsuzawa, C. Nishitani, N. Hyakushima, T. Shimizu, H. Sano, N. Matsushima, K. Fukase, and Y. Kuroki
Recombinant Soluble Forms of Extracellular TLR4 Domain and MD-2 Inhibit Lipopolysaccharide Binding on Cell Surface and Dampen Lipopolysaccharide-Induced Pulmonary Inflammation in Mice
J. Immunol., December 1, 2006; 177(11): 8133 - 8139.
[Abstract] [Full Text] [PDF]


Home page
FASEB J.Home page
M. Mancek-Keber and R. Jerala
Structural similarity between the hydrophobic fluorescent probe and lipid A as a ligand of MD-2
FASEB J, September 1, 2006; 20(11): 1836 - 1842.
[Abstract] [Full Text] [PDF]


Home page
JEMHome page
A. Macagno, M. Molteni, A. Rinaldi, F. Bertoni, A. Lanzavecchia, C. Rossetti, and F. Sallusto
A cyanobacterial LPS antagonist prevents endotoxin shock and blocks sustained TLR4 stimulation required for cytokine expression
J. Exp. Med., June 12, 2006; 203(6): 1481 - 1492.
[Abstract] [Full Text] [PDF]


Home page
J. Lipid Res.Home page
C. R. H. Raetz, T. A. Garrett, C. M. Reynolds, W. A. Shaw, J. D. Moore, D. C. Smith Jr., A. A. Ribeiro, R. C. Murphy, R. J. Ulevitch, C. Fearns, et al.
Kdo2-Lipid A of Escherichia coli, a defined endotoxin that activates macrophages via TLR-4
J. Lipid Res., May 1, 2006; 47(5): 1097 - 1111.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
P. Massari, A. Visintin, J. Gunawardana, K. A. Halmen, C. A. King, D. T. Golenbock, and L. M. Wetzler
Meningococcal Porin PorB Binds to TLR2 and Requires TLR1 for Signaling
J. Immunol., February 15, 2006; 176(4): 2373 - 2380.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Website Copyright © 2005 by The American Association of Immunologists, Inc. All rights reserved.
All Contents Copyright © 2005 by The American Association of Immunologists, Inc. All rights reserved.